Updated Monday, 11/9.
The US IPO market remains relatively quiet following election week, with three biotechs and one SPAC scheduled to raise $340 million in the week ahead.
Oncology biotech IN8bio (INAB) plans to raise $75...read more
Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the breaks as we near the election, with just one new IPO filing. SPAC activity continued unabated however as nine submitted initial filings. ...read more
Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, raised $190 million by offering 10 million shares at $19, above the range of $17 to $18. The company originally filed to offer 7.4 million...read more
Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, raised the proposed deal size for its upcoming IPO on Thursday. The Cambridge, MA-based company now plans to raise $175 million by offering 10...read more
US IPO Week Ahead: Biotechs break the post-election ice in a 3 IPO week
Updated Monday, 11/9. The US IPO market remains relatively quiet following election week, with three biotechs and one SPAC scheduled to raise $340 million in the week ahead. Oncology biotech IN8bio (INAB) plans to raise $75...read more
US IPO Weekly Recap: Solar technology shines in a 9 IPO week
Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the breaks as we near the election, with just one new IPO filing. SPAC activity continued unabated however as nine submitted initial filings. ...read more
CNS biotech Praxis Precision Medicines prices upsized IPO above the range at $19
Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, raised $190 million by offering 10 million shares at $19, above the range of $17 to $18. The company originally filed to offer 7.4 million...read more
CNS biotech Praxis Precision Medicines increases deal size by 39% ahead of $175 million IPO
Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, raised the proposed deal size for its upcoming IPO on Thursday. The Cambridge, MA-based company now plans to raise $175 million by offering 10...read more